Explore RLT services
Our all-encompassing service aims to simplify the RLT journey and minimise time-to-treatment for your eligible patients.
What are you looking for?
top
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Image
Image
Pluvicto resources
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Pluvicto is available in the United Kingdom to eligible private patients.
Resources for patients
To be shared with adult patients in the UK who have been prescribed Pluvicto for their PSMA-positive mCRPC or for whom the prescribing decision has been made.
The resources do not replace the Patient Information Leaflet (PIL) that comes with Pluvicto or advice from the patient’s healthcare team.
To access the PIL for Pluvicto patients in the UK, please visit the electronic medicines compendium (emc) website.
Image
177Lu, lutetium; AR, androgen receptor; mCRPC, metastatic castration-resistant prostate cancer; PIL, patient information leaflet; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.
Reference
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.
UK | October 2025 | FA-11470230
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.